Sage Journals: Discover world-class research

Abstract

Background:

Neutralizing antibodies (NAb) affect efficacy of interferon-beta (IFN-b) treatment in multiple sclerosis (MS) patients. NAbs evolve in up to 44% of treated patients, usually between 6–18 months on therapy.

Objectives:

To investigate whether early binding antibody (BAb) titers or different IFN-b biomarkers predict NAb evolution.

Methods:

We included patients with MS or clinically isolated syndrome (CIS) receiving de novo IFN-b treatment in this prospective European multicenter study. Blood samples were collected at baseline, before and after the first IFN-b administration, and again after 3, 12 and 24 months on that therapy; for determination of NAbs, BAbs, gene expression of MxA and protein concentrations of MMP-9, TIMP-1, sTRAIL, CXCL-10 and CCL-2.

Results:

We found that 22 of 164 (13.4%) patients developed NAbs during a median time of 23.8 months on IFN-b treatment. Of these patients, 78.9% were BAb-positive after 3 months. BAb titers ≥ 1:2400 predicted NAb evolution with a sensitivity of 74.7% and a specificity of 98.5%. Cross-sectionally, MxA levels were significantly diminished in the BAb/NAb-positive samples; similarly, CXCL-10 and sTRAIL concentrations in BAb/NAb-positive and BAb-positive/NAb-negative samples, respectively, were also diminished compared to BAb/NAb-negative samples.

Conclusions:

BAb titers reliably predict NAbs. CXCL-10 is a promising sensitive biomarker for IFN-b response and its abrogation by anti-IFN-b antibodies.

Keywords

Binding antibody biomarker clinically-isolated syndrome CXCL-10 drug resistance interferon-beta multicenter study multiple sclerosis myxovirus protein A neutralizing antibody sTRAIL

Get full access to this article

View all access options for this article.

References

Deisenhammer

. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: Prevalence and impact on outcomes. CNS Drugs 2009; 23: 379–396.

Perini

Calabrese

Biasi

. The clinical impact of interferon beta antibodies in relapsing–remitting MS. J Neurol 2004; 251: 305–309.

Sorensen

Koch-Henriksen

Ross

. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33–39.

Gneiss

Tripp

Reichartseder

. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006; 12: 731–737.

Mayr

Berek

Deisenhammer

. Evolution of interferon-beta binding antibodies in MS patients may predict development of neutralizing antibodies. Eur J Neurol 2003; 10: 462–464.

Deisenhammer

Reindl

Harvey

. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239–1243.

Von Wussow

Jakschies

Hochkeppel

. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990; 20: 2015–2019.

Polman

Bertolotto

Deisenhammer

. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740–750.

Lünemann

Waiczies

Ehrlich

. Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells. J Immunol 2002; 168: 4881–4888.

10.

Buttmann

Merzyn

Hofstetter

. TRAIL, CXCL10 and CCL2 plasma levels during long-term interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol 2007; 190: 170–176.

11.

Kurne

Guc

Canpinar

. Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: Evaluation of expression under immunomodulatory therapy. Acta Neurol Scand 2011; 123: 8–12.

12.

Buttmann

Merzyn

Rieckmann

. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol 2004; 156: 195–203.

13.

Sellebjerg

Krakauer

Hesse

. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 2009; 16: 1291–1298.

14.

Comabella

Río

Espejo

. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol 2009; 130: 145–150.

15.

Alexander

Harris

Wells

. Alterations in serum MMP-8, MMP-9, IL-12 p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 2010; 16: 801–809.

16.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the “McDonald Criteria.” Ann Neurol 2005; 58: 840–846.

17.

Farrell

Kapoor

Leary

. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler 2008; 14: 212–218.

18.

Lam

Farrell

Aziz

. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Meth 2008; 336: 113–118.

19.

Gneiss

Brugger

Millonig

. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult Scler 2008; 14: 830–836.

20.

Millonig

Rudzki

Holzl

. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): A pilot study. Mult Scler 2009; 15: 977–983.

21.

Schellekens

. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457–462.

22.

Kivisäkk

Alm

Fredrikson

. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 2000; 7: 27–34.

23.

Kivisäkk

Alm

Tian

. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis. Mult Scler 1997; 3: 184–190.

24.

Pachner

Cadavid

Wolansky

. Effect of anti-IFNbeta antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009; 73: 1485–1492.

25.

Sominanda

Hillert

Fogdell-Hahn

. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008; 79: 57–62.

26.

Bertolotto

Malucchi

Milano

. Interferon beta neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations. Immunopharmacol 2000; 48: 95–100.

27.

Cepok

Schreiber

Hoffmann

. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 2009; 66: 1216–1223.

28.

Gilli

F, Marnetto F

Caldano

. Biological markers of interferon beta therapy: Comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006; 12: 47–57.

29.

Hong

Zang

Hutton

. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol 2004; 152: 126–139.

30.

Pachner

Dail

Pak

. The importance of measuring IFN beta bioactivity: Monitoring in MS patients and the effect of anti-IFN beta antibodies. J Neuroimmunol 2005; 166: 180–188.

31.

Gneiss

Tripp

Ehling

. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol 2006; 174: 174–179.

32.

Gibbs

Oger

. A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res 2008; 28: 713–723.

33.

Hegen

Schleiser

Gneiss

. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 2012; 18: 610–615.

34.

Gilli

Hoffmann

Sala

. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis. Mult Scler 2006; 12: 738–746.

35.

Bendtzen

. Anti-IFN BAb and NAb antibodies: A minireview. Neurology 2003; 61: S6–10.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

0.31 MB

0.05 MB

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

Abstract

Background:

Objectives:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material